Sugi Predict

Sugi Predict / Compounds / SCHEMBL4992360

SCHEMBL4992360

SCHEMBL4992360

CC(=O)CSCC(N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 5/20 0.53
▸ NOS1 P29475 3/20 0.53
▸ NOS3 P29474 2/20 0.53
▸ ARG1 P05089 1/20 0.50
▸ ARG2 P78540 1/20 0.50
▸ SLC7A5 Q01650 1/20 0.41
▸ BHMT Q93088 3/20 0.41
▸ GRIK1 P39086 1/20 0.41
▸ BHMT2 Q9H2M3 1/20 0.40
▸ KIF11 P52732 3/20 0.40
▸ PMP22 Q01453 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ SLC7A11 Q9UPY5 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ SLC1A3 P43003 1/20 0.38
▸ SLC1A2 P43004 1/20 0.38
▸ SLC1A1 P43005 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4992347 1.00 NOS2 (0.53) NOS2NOS1NOS3ARG1ARG2
SCHEMBL13410552 0.85 NOS2 (0.51) NOS2NOS1NOS3ARG1ARG2
SCHEMBL14286756 0.84 NOS2 (0.38) NOS2NOS1NOS3ARG1ARG2
SCHEMBL24919549 0.84 NOS2 (0.38) NOS2NOS1NOS3ARG1ARG2
SCHEMBL10187369 0.83 NOS2 (0.50) NOS2NOS1NOS3ARG1ARG2
SCHEMBL2781165 0.82 ARG1 (0.53) NOS2NOS1NOS3ARG1ARG2
Carbocysteine SCHEMBL20854 0.82 BHMT (0.59) NOS2NOS1NOS3ARG1ARG2
SCHEMBL18788686 0.82 ARG1 (0.53) NOS2NOS1NOS3ARG1ARG2
Carbocysteine SCHEMBL6762355 0.82 BHMT (0.59) NOS2NOS1NOS3ARG1ARG2
Carbocysteine SCHEMBL69149 0.82 BHMT (0.59) NOS2NOS1NOS3ARG1ARG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-11-02 — — US disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 — — EP disclosed
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. 2023-07-20 — — US disclosed
EP-3225248-B1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-06-07 — — EP disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 — — US disclosed
US-20230028168-A1 Modified Relaxin Polypeptides and Their Uses AMBRX, INC. 2023-01-26 — — US disclosed
US-20110294161-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2011-12-01 — — US disclosed
WO-2011087808-A1 MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2011-07-21 — — WO disclosed
WO-2011087810-A1 MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2011-07-21 — — WO disclosed
WO-2011079293-A1 TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND POLYPEPTIDES AND THEIR USES AMBRX, INC (US) 2011-06-30 — — WO disclosed
EP-2284191-A2 Process for the preparation of hGH Ambrx, Inc. (US) 2011-02-16 — — EP disclosed
WO-2010006214-A1 FGF-21 NEUTRALIZING ANTIBODIES AND THEIR USES AMBRX, INC. (US) 2010-01-14 — — WO disclosed
WO-2009117622-A2 MODIFIED FGF-23 POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2009-09-24 — — WO disclosed
WO-2009067636-A2 MODIFIED INSULIN POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2009-05-28 — — WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 — — US disclosed
WO-2006069220-A9 MODIFIED HUMAN GROWTH HORMONE AMBRX INC (US) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF IL2, IL2RA, TAP2 NOS2 1049/4885NOS1 4161/4885NOS3 3388/4885
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 NOS2 1667/4885NOS1 2210/4885NOS3 2480/4885
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 NOS2 4241/4885NOS1 4297/4885NOS3 3906/4885
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES CSF3R, GMFG, HDGF NOS2 2298/4885NOS1 3226/4885NOS3 2522/4885
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates CD63, CD74, CD99 NOS2 2216/4885NOS1 2705/4885NOS3 2785/4885
US-20230028168-A1 Modified Relaxin Polypeptides and Their Uses RXFP1, RXFP2, RXFP4 NOS2 1488/4885NOS1 2469/4885NOS3 1453/4885
US-11786578-B2 Modified relaxin polypeptides and their uses RXFP1, RXFP2, RXFP3 NOS2 396/4885NOS1 624/4885NOS3 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.